expression profile that distinguishes a unique leukemia. Few investigations to date into involvement of non-haematopoietic stromal cells (nHSCs) in haematological malignancies have provided divergent results. 1 Although one report has demonstrated that nHSC do not participate in chronic myeloid leukaemia (Keating et al., Blood 1986; 68: 1449, abstract), a study of patients with myeloproliferative disorders that were heterozygous for glucose-6-phosphate dehydrogenase showed that nHSC from adherent layers of long-term marrow cultures derived from the same clonal progenitors as the multipotent stem cell disorder.
2 Furthermore, we recently described a cell line from a patient with acute lymphoblastic leukaemia that concomitantly exhibited markers of nHSC and of haematopoie- Table 1 Immunophenotypic and molecular analysis of nHSC from 20 patients with cMPDs Abbreviations: AR, % of V617F mutated allele; ET, essential thrombocythemia; IM, idiopathic myelofibrosis; LLME, leucyl-leucine methyl ester; PV, polycythemia vera.
Letters to the Editor tic stem cells. 3 As a single activating mutation in Janus kinase (JAK-2) is considered a very good new marker of clonality in chronic myeloproliferative syndromes (cMPDs), 4 we determined whether the marrow microenvironment is an abnormal stromal compartment carrying the JAK-2 mutation. After obtaining informed consent, we generated bone marrow mesenchymal cells 5 from 20 patients (10 with polycythemia vera, five with essential thrombocythemia and five with idiopathic myelofibrosis) carrying the V617F mutation (Table 1) . After a median of 2 months, nHSC were detached and analysed with direct fluorescence for expression of CD45-FITC, CD90-FITC, CD105-FITC (Beckman-Coulter Corporation, Hialeah, FL, USA) and STRO1-PE (Caltag Laboratories, Burlingame, CA, USA) by Epics XL cytometer (Coulter). Polymerase chain reaction (PCR) analysis determined CD45 mRNA expression. 3 Cells were analysed for the Jak-2 mutation by allele-specific PCR 4 and by microelectronic DNA chip that allows automated calculation of the allelic ratio (mutated V617F vs wild type). 6 No differences emerged in the generation of the stromal layer from the different cMPDs. Furthermore, the cases with allelic ratios 450% V617F did not show any disadvantages in the stromal generation. In 15/ 20 cases, flow cytometry analysis revealed that nHSC were negative for CD45 and positive for CD90, CD105 and STRO-1. The other five cases still had residual haematopoietic cells as shown by 1-2% positivity for CD45 at immunophenotyping and strong PCR positivity for CD45 mRNA expression. Five other cases had faint positivity at PCR and 10 were negative. The distribution of CD45 PCR-positive/negative cases was not disease specific. V617F Jak-2 mutation analysis demonstrated that the mutation was not present in the 10 cases that were CD45 negative at immunophenotyping and PCR. A faint positivity emerged in cases with only mRNA positivity at CD45 PCR. The mutation was strongly present in the five cases that were CD45 positive by cytofluorimetry analysis and/or PCR. All JAK-2-positive cases were treated with leucyl-leucine methyl ester, the antilysosomal compound 5 that induces selective depletion of monocyte-macrophages. After treatment, all cases were JAK-2 negative. Macrophages persisting long term in cultures may account for the false positive results reported by Singer et al.
